Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

Core Viewpoint - Asahi Kasei Corporation has acquired over 90% of Calliditas Therapeutics' outstanding shares and intends to initiate compulsory redemption of the remaining shares, prompting Calliditas' Board of Directors to take corporate actions [1]. Delisting and Deregistration - Calliditas' Board has resolved to apply for the delisting of its common shares from Nasdaq Stockholm and its American Depositary Shares (ADSs) from the Nasdaq Global Select Market at Asahi Kasei's request [2]. - The last trading day for Calliditas' common shares on Nasdaq Stockholm will be announced once confirmed by Nasdaq Stockholm [3]. - The company plans to file a Form 25 with the U.S. Securities and Exchange Commission (SEC) around September 13, 2024, with the delisting of the ADSs expected to take effect around September 23, 2024 [4]. Extraordinary General Meeting - An Extraordinary General Meeting has been convened by Calliditas' Board at Asahi Kasei's request, scheduled for September 30, 2024, to elect a new Board of Directors [5]. Company Overview - Calliditas Therapeutics is a biopharma company based in Stockholm, Sweden, focused on developing treatments for orphan indications with significant unmet medical needs. Its common shares are listed on Nasdaq Stockholm and its ADSs on the Nasdaq Global Select Market [6].